Provectus Biopharmaceuticals (NYSEMKT:PVCT) announces that the Japan Patent Office has granted and the European Patent Office allowed its patent application for the combination of PV-10 with systemic immunomodulatory therapy.
Pfizer (NYSE:PFE) is the co-assignee.
PV-10 is an injectable formulation of Rose Bengal that is under investigation as an ablative immunotherapy for solid tumor cancers. Provectus has received orphan drug designations of PV-10 from the FDA for melanoma and hepatocellular carcinoma indications.
Subscribe for full text news in your inbox